ANL 10.33 Decreased By ▼ -0.06 (-0.58%)
ASC 9.07 Decreased By ▼ -0.04 (-0.44%)
ASL 11.20 Decreased By ▼ -0.10 (-0.88%)
AVN 78.38 Decreased By ▼ -0.62 (-0.78%)
BOP 5.43 Decreased By ▼ -0.10 (-1.81%)
CNERGY 5.37 Increased By ▲ 0.01 (0.19%)
FFL 6.63 Increased By ▲ 0.02 (0.3%)
FNEL 5.95 No Change ▼ 0.00 (0%)
GGGL 11.06 Decreased By ▼ -0.04 (-0.36%)
GGL 16.53 Increased By ▲ 0.03 (0.18%)
GTECH 8.41 Decreased By ▼ -0.09 (-1.06%)
HUMNL 7.16 No Change ▼ 0.00 (0%)
KEL 3.09 Increased By ▲ 0.01 (0.32%)
KOSM 3.04 Decreased By ▼ -0.01 (-0.33%)
MLCF 27.00 Increased By ▲ 0.40 (1.5%)
PACE 3.00 Decreased By ▼ -0.03 (-0.99%)
PIBTL 6.07 Increased By ▲ 0.03 (0.5%)
PRL 18.20 Increased By ▲ 0.09 (0.5%)
PTC 7.02 No Change ▼ 0.00 (0%)
SILK 1.16 Decreased By ▼ -0.01 (-0.85%)
SNGP 34.41 Increased By ▲ 0.86 (2.56%)
TELE 11.03 Decreased By ▼ -0.07 (-0.63%)
TPL 9.05 Decreased By ▼ -0.10 (-1.09%)
TPLP 20.04 Decreased By ▼ -0.49 (-2.39%)
TREET 29.50 Decreased By ▼ -0.23 (-0.77%)
TRG 77.05 Decreased By ▼ -0.35 (-0.45%)
UNITY 20.24 No Change ▼ 0.00 (0%)
WAVES 12.70 Decreased By ▼ -0.10 (-0.78%)
WTL 1.37 Decreased By ▼ -0.03 (-2.14%)
YOUW 4.80 Increased By ▲ 0.02 (0.42%)
BR100 4,079 Decreased By -33 (-0.8%)
BR30 15,121 Decreased By -46.5 (-0.31%)
KSE100 41,298 Decreased By -467.9 (-1.12%)
KSE30 15,697 Decreased By -237.2 (-1.49%)

LONDON: European equities fell in opening deals on Tuesday after the head of Moderna warned current coronavirus vaccines might be less effective at fending off the Omicron variant.

In initial trade, London’s benchmark FTSE 100 index reversed 0.9 percent to 7,047.14 points.

In the eurozone, Frankfurt’s DAX shed 0.9 percent to 15,137.86 points and the Paris CAC 40 lost 1.1 percent to 6,702.83.

Asian bourses and oil prices also took a tumble following the remarks.

Moderna chief executive Stephane Bancel’s comments, in an interview with the Financial Times, sent traders running for cover.

“There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,” he told the daily business newspaper.

The high amount of mutations on Omicron and its swift spread in South Africa indicated the present jabs would need to be tweaked, he indicated.

“Bancel ... predicted existing vaccines would struggle with the Omicron variant,” said CMC Markets analyst Michael Hewson.

The Moderna chief “warned it would take months for pharmaceutical companies to manufacture enough jabs at a sufficient scale to make a difference”, Hewson added.

“His tone contrasts with the likes of Pfizer and BioNTech was suggested any new vaccine would be able to modified fairly quickly.”

Comments

Comments are closed.